Insider trade

Genprex (GNPX): Director sold ~$10

Brent M Longnecker, Director at Genprex, sold ~$10 of Genprex shares.

~$10
Approx. value · 8 sh @ $1.23
9,157
Holds after · shares reported
Traded
Apr 14, 2026
Filed
Apr 15, 2026

What stands out in this filing

  • The sale was 0.1% of the shares this insider held before it; the filing reports 9,157 shares afterwards.
  • 8 shares at an average of $1.23 each, as reported on the form.
  • No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 5, 2026CongressDisclosed purchase of GNPX — reported range $1,001 - $15,000
  2. Apr 14, 2026 · this disclosureInsiderDirector sold ~$10 of GNPX shares in the open market

What came next

  1. Apr 14, 2026InsiderDirector sold ~$12 of GNPX shares in the open market
  2. Jun 10, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On June 10, 2026, Genprex, Inc. (“Genprex” or the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company’s common stock closed at less than $1.00 per share over the previous 30 consecutive business days and as a result is not in compliance with the $1.00 minimum bid price requirement set forth in…”
  3. Jun 18, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 18, 2026 at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of Genprex, Inc. (the “Company” or “Genprex”), the Company’s stockholders approved the Company’s amended and restated 2018 Equity Incentive Plan (the “2018 Plan”, and as so amended and restated, the “Amended Equity Plan”).”
  4. Jul 13, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 2 more items)
  5. Jul 29, 2026Company filing · Form 8-K · Listing notice, Other newsReceived a notice from its stock exchange, and reported other company news“On July 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified Genprex, Inc. (the “Company” or “Genprex”) that it has granted the Company’s request to continue the Company’s listing on The Nasdaq Capital Market (“Nasdaq”) and grant an exception (the “Exception”) to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”),…”
  6. Aug 4, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On August 4, 2026, the Company was formally notified that the Panel determined that the Company has regained compliance with the Bid Price Requirement.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Genprex

OQRO holds no insider, Congress, fund or contract record for Genprex dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GNPX page.

Other recent filings by Brent M Longnecker, Director

The full history of Brent M Longnecker, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Genprex (GNPX) insider traded, and how much?

Brent M Longnecker, Director at Genprex, sold ~$10 of Genprex shares. 8 shares at $1.23.

When did it happen, and when was it made public?

Traded: Apr 14, 2026. Filed: Apr 15, 2026. That is 1 day between the two dates.

What stands out in this filing?

The sale was 0.1% of the shares this insider held before it; the filing reports 9,157 shares afterwards. 8 shares at an average of $1.23 each, as reported on the form. No footnote on the form refers to a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean GNPX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Genprex

Everything OQRO holds on this company is on its GNPX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data